2 with intravenous insulin became popular after initial reports suggesting that such treatment led to decreased in-hospital and 30-day mortality (1-3 ). Such treatment became controversial when several subsequent studies failed to confirm the improved clinical outcomes (4 -6 ). The latter studies, however, used different methods for glucose measurement, and the measurements typically were made less frequently (7 ).
required of glucose assays, and what impact morefrequent measurement has on patient outcomes and/or the analytical performance requirements of glucose measurement. Although earlier modeling studies of these questions have used established physiologic models of glucose homeostasis (10, 11 ) , what makes the current modeling studies unique and so important is that the models in these studies are based on data from actual ICU patients.
Modeling
More than 350 models of glucose homeostasis were published as of 2003; the number is now undoubtedly much larger. In our simulation studies (10, 11 ), we chose a model based on the classic minimal model of Tofello et al. (12 ) . Although the minimal model, in its many variations, has drawbacks, the approach has been deemed "indisputably useful" (13 ). This method offers the advantage of freely manipulable parameters allowing the exploration of a wide range of starting glucose concentrations, a wide range of constant or varying insulin sensitivities, and a long duration of monitoring (and thus stable The optimal MARD scores of Ͻ10 or Ͻ11 suggested, respectively, in Wilinska and Hovorka (8 ) and Van Herpe et al. (9 ) for CGM, in which glucose is measured frequently, correspond to upper TE limits as large as 20%-23% when z ϭ 1.65. Such a TE allowance is much larger than the TE limits currently under consideration for intermittent glucose measurement systems. The findings from these 2 studies suggest that the acquisition of glucose data more frequently by a CGM system carries definite advantages for management of glycemia, even when the analytical performance of a CGM is inferior to that recommended for meters used in intermittent glucose monitoring. The results in these 2 reports also support the conclusion of our earlier studies, which used a third simulation modeling approach: quality specifications for imprecision of glucose meters are not transferable to CGM (11 ).
The models agree that control of glycemia is intimately related to (a) the analytical performance of the glucose measurement system, (b) the frequency of the measurements, and (c) the protocol by which a measured glucose is translated into an intervention. Moreover, these 3 determinants are interrelated. The implications for design of glucose-measuring systems are becoming clearer, as are implications regarding the frequency of measurements in the face of constraints on nursing time in ICUs. Given the growing evidence that patient outcomes, including mortality, are predicted by control of glycemia, these issues demand attention.
All modeling studies carry the same conundrum expressed years ago by the statistician George E.P. Box, who stated, "Essentially, all models are wrong, but some are useful" (15 ). All of the models described to study the question of the effects of measurement imprecision on control of glycemia are admittedly imperfect. But the fact that 3 independent models, distinct from each other in their construction, produce similar conclusions makes the results of those models more credible. Wilinska 
